GlassScriptPhysician profile
Chandresh B Shah
NPI 1770655987
$4,029.98
in general payments reported to CMS, 2019-2025
25 companies · $483 in 2025
The $483 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $456 · 2020: $320 · 2021: $1,192 · 2022: $427 · 2023: $647 · 2024: $505 · 2025: $483.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,635.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,634.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Paratek Pharmaceuticals, INC. | $988.52 | 2021-2025 | Nuzyra, Xhance |
| Astrazeneca Pharmaceuticals LP | $832.30 | 2022-2025 | Airsupra, Breztri, Farxiga |
| Abbvie INC. | $438.12 | 2022-2025 | Vraylar, Ubrelvy, Qulipta |
| Janssen Pharmaceuticals, INC | $356.00 | 2019 | |
| Pfizer INC. | $227.44 | 2020-2025 | |
| Orexo US, INC. | $197.18 | 2019-2021 | |
| Horizon Therapeutics Plc | $169.88 | 2020-2022 | |
| Novo Nordisk INC | $139.81 | 2021-2025 | Ozempic |
| Lilly USA, LLC | $98.76 | 2020-2021 | |
| Idorsia Pharmaceuticals US INC | $87.04 | 2022-2025 | Quviviq, Quviviq |
| Kowa Pharmaceuticals America, INC. | $78.20 | 2022-2024 | Seglentis, Zoryve, Livalo |
| Imperative Care, INC | $75.81 | 2025 | Prodigy Catheter |
| Masimo Corporation | $47.64 | 2023 | Emma and Isa |
| Ucb, INC. | $46.17 | 2025 | Rystiggo |
| Alkermes, INC. | $44.01 | 2019-2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $35.40 | 2022 | |
| Amgen INC. | $28.29 | 2024 | Repatha, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.09 | 2024 | Jardiance |
| Genentech USA, INC. | $20.79 | 2021 | |
| Neurocrine Biosciences, INC. | $17.67 | 2023 | Ingrezza |
| Biodelivery Sciences International, INC. | $17.46 | 2019 | |
| Glaxosmithkline, LLC. | $17.14 | 2025 | Shingrix |
| Exact Sciences Corporation | $16.14 | 2023 | Cologuard Collection Kit |
| Eisai INC. | $14.12 | 2021 | |
| Merck Sharp & Dohme LLC | $12.00 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chandresh Shah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.